Article

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses

2019-12-15

Abstract excerpt

<h4>Purpose</h4> There remains an unmet need for preclinical models to enable personalized therapy for ovarian cancer (OC) patients. Recently, patient-derived organoid (PDO) cultures of patients with OC have been established that faithfully represent the histopathological features and genomic landscape of the patient tumor. In this study, we evaluate the capacity of OC PDOs to predict clinical drug response and fu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1099848a-9bf8-5429-b936-f4869e6c80d2
DOI: 10.1101/2019.12.12.19014712

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesDOI 10.1101/2019.12.12.19014712Read

Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesSemantic proximity Read

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseSemantic proximity Read

Patient-Derived Organoids Functionally Stratify Epithelial Ovarian Cancer into Clinically Relevant Chemotherapy Response PhenotypesSemantic proximity Read

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.Semantic proximity Read

The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testingSemantic proximity Read

Organoid Models Established from Primary Tumors and Patient-Derived Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer PatientsSemantic proximity Read

Longitudinal Prediction of Drug Response in High-Grade Serous Ovarian Cancer Organoid Cultures Aligning with Clinical ResponsesSemantic proximity Read

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity Read

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testingSemantic proximity Read

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read

Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic VulnerabilitiesSemantic proximity Read